The Pan American Health Organization (PAHO) Regional Revolving Funds delivered more than 234 million vaccine doses and 13 million diagnostic tests in 2025, reaching an estimated 85 million people across the Americas.
Through pooled procurement, countries secured over US$900 million in health supplies at affordable prices—often achieving savings of around 50%. Nearly every country and territory in the region, except Canada and the United States, accessed supplies through the mechanism, along with several Caribbean territories and public institutions.
A major milestone in 2025 was the growth of regional manufacturing. Procurement from regional producers rose from 1.5% in 2020 to 23%, with capacity expected to reach 40% soon, strengthening supply security and reducing reliance on global markets.
Countries also expanded access to new vaccines and treatments, including dengue and RSV vaccines, the 9-valent HPV vaccine, malaria diagnostics, HIV and tuberculosis treatments, and high-cost medicines for cancer and other serious conditions—some negotiated at discounts of up to 90%.
Demand linked to PAHO’s Elimination Initiative increased significantly, with a 20% rise in HIV and hepatitis testing and 10 million additional malaria tests compared to 2024.
The PAHO Regional Revolving Funds—comprising the Revolving Fund for Access to Vaccines and the Strategic Fund for Public Health Supplies—continue to strengthen immunization programmes, improve emergency response, and advance disease elimination across the Americas.
